ES3059224T3 - Compounds for prevention and treatment of obesity and related disorders - Google Patents
Compounds for prevention and treatment of obesity and related disordersInfo
- Publication number
- ES3059224T3 ES3059224T3 ES20767302T ES20767302T ES3059224T3 ES 3059224 T3 ES3059224 T3 ES 3059224T3 ES 20767302 T ES20767302 T ES 20767302T ES 20767302 T ES20767302 T ES 20767302T ES 3059224 T3 ES3059224 T3 ES 3059224T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- subject
- day
- substituted
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812314P | 2019-03-01 | 2019-03-01 | |
| PCT/US2020/020707 WO2020180821A1 (en) | 2019-03-01 | 2020-03-02 | Compounds for prevention and treatment of obesity and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3059224T3 true ES3059224T3 (en) | 2026-03-19 |
Family
ID=72338080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20767302T Active ES3059224T3 (en) | 2019-03-01 | 2020-03-02 | Compounds for prevention and treatment of obesity and related disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12357596B2 (https=) |
| EP (1) | EP3931179B1 (https=) |
| JP (1) | JP7598195B2 (https=) |
| CN (1) | CN114072376B (https=) |
| CA (1) | CA3132318A1 (https=) |
| ES (1) | ES3059224T3 (https=) |
| WO (1) | WO2020180821A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024249415A1 (en) * | 2023-05-26 | 2024-12-05 | Abrexa Pharmaceuticals, Inc. | Compounds for use in organ preservation and organ transplantation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017540A (en) * | 1968-03-04 | 1977-04-12 | The Upjohn Company | Method of use, composition, and compounds |
| US20100004302A1 (en) * | 2003-04-29 | 2010-01-07 | Connie Erickson-Miller | Methods for Treating Degenerative Diseases/Injuries |
| US20070238700A1 (en) * | 2006-04-10 | 2007-10-11 | Winzenberg Kevin N | N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites |
| US8779002B2 (en) * | 2007-10-15 | 2014-07-15 | Salk Institute For Biological Studies | Methods for treating a variety of diseases and conditions, and compounds useful therefor |
| WO2017112701A1 (en) * | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
-
2020
- 2020-03-02 EP EP20767302.1A patent/EP3931179B1/en active Active
- 2020-03-02 ES ES20767302T patent/ES3059224T3/es active Active
- 2020-03-02 CN CN202080030234.4A patent/CN114072376B/zh active Active
- 2020-03-02 CA CA3132318A patent/CA3132318A1/en active Pending
- 2020-03-02 US US17/435,678 patent/US12357596B2/en active Active
- 2020-03-02 JP JP2021551942A patent/JP7598195B2/ja active Active
- 2020-03-02 WO PCT/US2020/020707 patent/WO2020180821A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3931179A1 (en) | 2022-01-05 |
| CN114072376A (zh) | 2022-02-18 |
| WO2020180821A1 (en) | 2020-09-10 |
| CA3132318A1 (en) | 2020-09-10 |
| EP3931179C0 (en) | 2025-12-10 |
| CN114072376B (zh) | 2024-12-20 |
| US12357596B2 (en) | 2025-07-15 |
| EP3931179A4 (en) | 2022-11-30 |
| US20220133657A1 (en) | 2022-05-05 |
| JP2022523792A (ja) | 2022-04-26 |
| JP7598195B2 (ja) | 2024-12-11 |
| EP3931179B1 (en) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9907787B2 (en) | Method of supplementing the diet and ameliorating oxidative stress | |
| US8426368B2 (en) | Method of ameliorating oxidative stress and supplementing the diet | |
| ES3036920T3 (en) | Compounds for prevention and treatment of post-operative cognitive dysfunction | |
| KR20200084343A (ko) | 중수소 농축 N-아세틸시스테인 아미드(D-NACA) 및 (2R,2R')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(Di-NACA)의 제조방법 및 산화 스트레스를 포함하는 질환을 치료하기 위한 D-NACA 및 Di-NACA의 사용방법 | |
| DE4218572A1 (de) | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E | |
| IL301015A (en) | Formulations of anti-viral compounds | |
| JP7740810B2 (ja) | 呼吸困難に起因する集中治療後の認知機能障害及び認知障害の予防及び治療のための化合物 | |
| US9060967B2 (en) | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| ES3059224T3 (en) | Compounds for prevention and treatment of obesity and related disorders | |
| WO2024249415A1 (en) | Compounds for use in organ preservation and organ transplantation | |
| US6034126A (en) | Method for treating glycol poisoning | |
| US11938104B1 (en) | Compositions and methods for prevention and treatment of coronavirus and related disorders | |
| US12496281B2 (en) | Compounds for prevention and treatment of hemorrhage and vasculature instability | |
| BR122025010953A2 (pt) | Compostos de d-anfetamina, composição que compreende os mesmos, kit que compreende a dita composição e uso terapêutico dos ditos compostos | |
| ES2356828T3 (es) | Preparados para gotas que comprenden dimentindeno. | |
| HK40089435A (zh) | 预防和治疗重症监护後认知功能障碍和呼吸窘迫致认知功能障碍的化合物 |